Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Unity Biotechnology Inc
UBXCurrent price
0.97 USD
+0.018 USD (+1.89%)
Last closed
0.93 USD
Company
unitybiotechnology.com
ISIN
US91381U1016
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
16 361 572 USD
Yield for 12 month
-34.46 %
1Y
3Y
5Y
10Y
15Y
UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Address: 285 East Grand Avenue, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-19 699 000 USD
Current Quarter
+664 000 USD
Last Quarter
+664 000 USD
Key Figures UBX
1 year
3 years
5 years
10 years
EBITDA
-27 599 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-34.43 %
PEG Ratio
–
Return On Equity TTM
-148.97 %
Wall Street Target Price
5.00 USD
Revenue TTM
–
Book Value
0.39 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
-13 006 000 USD
Earnings per share
-1.54 USD
Diluted Eps TTM
-1.54 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics UBX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History UBX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
20.10.2022
Stock Valuation UBX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
29.79
Price Sales TTM
6.54
Enterprise Value EBITDA
-0.23
Price Book MRQ
2.47
Financials UBX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators UBX
For 52 weeks
0.85 USD
3.10 USD
50 Day MA
1.53 USD
Shares Short Prior Month
639 936
200 Day MA
1.47 USD
Short Ratio
3.50
Shares Short
704 778
Short Percent
4.22 %
BeatStart